Stockreport

Pluristem Therapeutics Announces Completion of 2nd Cohort and DSMB Approval to Enroll Final Cohort in Phase I Hematological Study of PLX-R18

Pluristem Therapeutics, Inc.  (PSTI) 
Last pluristem therapeutics, inc. earnings: 2/6 04:10 pm Check Earnings Report
US:NASDAQ Investor Relations: pluristem.com
PDF HAIFA, Israel, March 12, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel place [Read more]